Shareholder law firm launches securities fraud probe into Capricor Therapeutics after FDA advisory committee raised doubts about its heart‑failure therapy
Executive summary: Glancy Prongay Wolke & Rotter LLP announced it has commenced a securities fraud investigation into Capricor Therapeutics concerning the FDA’s review and advisory committee meeting about the company’s heart‑failure therapy. The investigation raises potential legal liability and could further depress the company’s stock, which already fell sharply after the FDA advisory committee’s skepticism.
Who is involved: Glancy Prongay Wolke & Rotter LLP (law firm), Capricor Therapeutics (NASDAQ: CAPR), the FDA advisory committee, and affected shareholders.
Likely next: Capricor may be required to preserve documents and respond to the law firm’s inquiries; the SEC could monitor the situation, and any ensuing lawsuit could lead to discovery, settlement, or trial.
Glancy Prongay Wolke & Rotter LLP said it opened an investigation on behalf of Capricor investors following the FDA’s advisory committee meeting, which questioned the statistical significance of the company’s Deramiocel therapy. The announcement comes after Capricor’s shares tumbled 60‑70% on July 27 when FDA briefing documents challenged the trial results. While the probe does not allege wrongdoing, it signals growing legal scrutiny that could lead to a class action suit and affect the company’s ability to raise capital.
Timeline
- — Pentair plc (PNR) Stockholders: Contact Robbins LLP Regarding its Ongoing Investigation (PR Newswire)
- — INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Photronics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PLAB (PR Newswire)
- — Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm (PR Newswire)
- — Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR) (PR Newswire)
Analysis — what this means
Sectors affected
- cardiovascular biotechnology
Historical parallels
- Levi & Korsinsky announced a pending investigation into Capricor on July 29, 2026 after a 60‑70% stock drop following FDA briefing doubts
Key entities
Sources
Open the full interactive case file on Beyond →